IoT

搜索文档
Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd
Globenewswire· 2025-07-22 20:36
WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd (“Yorkville”). The extinguishment of this convertible note, dated January 16, 2025, has cleared the Company’s outstanding debt obligations to Yorkville. David Mehalick, CEO of Coeptis Therapeutics Holdings, Inc., stated, “The extinguishment of ...
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
GlobeNewswire News Room· 2025-07-22 20:32
Ra’anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for ...
NKGen Biotech to Present at the Alzheimer's Association International Conference 2025
Globenewswire· 2025-07-22 20:05
SANTA ANA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present on the mechanism of action for troculeucel, enhanced non-genetically modified NK cell therapy, in Alzheimer’s disease during a poster presentation at the upcoming Alzheimer’s Association Intern ...
Danaher(DHR) - 2025 Q2 - Earnings Call Presentation
2025-07-22 20:00
Danaher Corporation Second Quarter 2025 Earnings Release July 22, 2025 2 Second Quarter 2025 Performance Summary $5,743 $5,936 Q2 2024 Q2 2025 Revenue +3.5% Core +1.5% FX +2.0% $1.72 $1.80 Q2 2024 Q2 2025 Adjusted Diluted Net Earnings Per Common Share +4.7% 27.3% 27.3% Q2 2024 Q2 2025 Adjusted Operating Profit Margin Flat ($ millions) Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or antic ...
科创板再迎2条新指数 科创民企相关指数即将发布
新华财经· 2025-07-22 19:37
新华财经上海7月22日电(记者杜康)科创板"开市"六周年之际,科创板指数体系再迎"新成员"。上海 证券交易所与中证指数有限公司22日宣布,将于2025年7月23日正式发布上证科创板民营企业指数(以 下简称"科创民企指数")和上证科创板民营企业50策略指数(以下简称"科创民企策略指数"),为市场 提供科创板民营企业领域的业绩基准和投资标的。 民营经济是资本市场重要的参与主体和组成部分。A股上市公司中,民营企业上市公司数量3478只;其 中,科创板民企上市公司数量422只,占比高达七成以上。在科创板中,民企上市公司总市值3.5万亿 元,营收总额0.9万亿元,分别占全部科创板证券的58.2%和68.0%。 2024年A股民营企业研发投入连续两年持续超过6500亿元。A股中,民营企业的研发支出占营收比例达 到3.8%,高于A股平均水平1.2个百分点。 记者获悉,即将发布的科创民企指数,选取科创板所有的民营企业上市公司证券作为指数样本,旨在全 面刻画科创板民营上市公司证券的整体表现。截至2025年6月底,指数样本422只,合计市值3.5万亿 元,其中有171家民营企业2024年实现营业收入、净利润双增长,37家营业收入 ...
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Globenewswire· 2025-07-22 19:30
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 29-30, 2025. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team shou ...
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
Globenewswire· 2025-07-22 19:30
TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled “Prevention Of NephroToxin Induced Acute Kidney Injury with Cilastatin” (PONTIAK) has commenced patient recruitment at its primary clinical sites in Alberta, Canada. The Phase II PONTIAK study aims to evaluate the efficacy of cilastatin in preventing AKI associated with nephrotoxic pharmaceuticals, which include common ...
uniQure to Announce Second Quarter 2025 Financial Results
Globenewswire· 2025-07-22 19:05
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 financial results before market open on Tuesday, July 29, 2025. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure's web ...
科创板开市六周年:589家上市!1.1万亿融资!总市值破7万亿!
国际金融报· 2025-07-22 18:48
2019年1月23日,中央深改委审议通过科创板及注册制总体实施方案,确立改革框架,加速制度落地。 2019年7月22日,科创板正式开市,首批25家企业上市,注册制试点落地,开启"硬科技"企业资本化新征程。 制图:佘诗婕 2018年11月5日,习近平主席在首届进博会宣布设立科创板并试点注册制,标志资本市场服务科技创新的重大制度创新启动,为注册制改革提 供"试验田"。 今天,科创板迎来开市6周年。 图片来源:证券时报网 夯实资本市场可持续发展基础 6年来,科创板以注册制改革为抓手,支持优质科技企业上市,IPO与再融资募集资金合计超1.1万亿元。 据统计,截至7月22日,科创板累计支持589家公司上市,IPO募集资金9257亿元,再融资募集资金1867亿元,总市值超过7万亿元。 其中诞生8家千亿市值企业,包括中芯国际(4352亿元)、海光信息、百济神州等,另有192家市值超百亿企业。 同时,科创板投资者回报机制不断完善,夯实资本市场可持续发展基础。 2024年,超六成公司推出现金分红方案,总额达388亿元,290家分红比例超30%,111家实施中期分红创历史新高。 470家次推出回购、增持方案,金额上限近380亿元 ...
科创板开市六周年:589家上市!1.1万亿融资!总市值破7万亿!
IPO日报· 2025-07-22 18:39
制图:佘诗婕 2018年11月5日 , 习近平主席在首届进博会宣布设立科创板并试点注册制 ,标志资本市场服务科技创新的重大制度创新启动,为注册制改革提 供"试验田"。 2019年1月23日 ,中央深改委审议通过科创板及注册制总体实施方案,确立改革框架,加速制度落地。 星标 ★ IPO日报 精彩文章第一时间推送 今天 , 科创板迎来开市6周年。 2019年7月22日,科创板正式开市,首批25家企业上市,注册制试点落地,开启"硬科技"企业资本化新征程。 图片来源:证券时报网 夯实资本市场可持续发展基础 6年来,科创板以注册制改革为抓手,支持优质科技企业上市,IPO与再融资募集资金合计超1.1万亿元。 据统计, 截至7月22日,科创板累计支持589家公司上市,IPO募集资金9257亿元,再融资募集资金1867亿元,总市值超过7万亿元。 其中 诞生8家千亿市值企业,包括中芯国际(4352亿元)、海光信息、百济神州等,另有192家市值超百亿企业 。 同时,科创板 投资者回报机制不断完善,夯实资本市场可持续发展基础。 2024年,超六成公司推出现金分红方案,总额达388亿元,290家分红比例超30%,111家实施中期分红 ...